中國生物科技服務(8037.HK)大漲超14% 與華大基因合資設新型肺炎檢測實驗室
格隆匯8月18日丨中國生物科技服務(8037.HK)今日盤中大漲14.56%報1.81港元,總市值17.5億港元。公司昨晚公佈,與華大基因合資註冊成立華昇診斷中心,主要業務為於香港提供醫學實驗室檢測服務。華昇診斷中心先前已經在香港設立一間新型冠狀病毒檢測實驗室,最近亦在香港額外設立及經營一間有16個氣膜的臨時實驗室,為香港市民提供新型冠狀病毒檢測,額外的實驗室每日可進行約10萬次單管測試,其將使華昇診斷中心總檢測能力由每日3萬次增加至13萬次,使其成為香港擁有高檢測能力的新型冠狀病毒檢測實驗室之一。目前華昇診斷中心已經進行超過10萬次新型冠狀病毒檢測。此外,華昇診斷中心亦為未來在香港發展健康碼系統做好準備,以迎接經濟及旅遊業復甦,以及邊境管制解除。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.